Sign Up Today and Learn More About EGenesis Stock
Invest in or calculate the value of your shares in EGenesis or other pre-IPO companies through EquityZen's platform.
EGenesis Stock (EGEN)
eGenesis tackles organ shortage with gene-edited pig organs. Their xenotransplantation technology offers a solution for patients in need by developing human-compatible organs from pigs.
EGenesis designs xenotransplantation for the benefit of human health.
About EGenesis Stock
Founded
2014
Headquarters
Cambridge, MA, US
Total Funding
150M
Industries
Science and Engineering, Health Care, Biotechnology
EGenesis designs xenotransplantation for the benefit of human health. Its technology helps transform xenotransplantation into a medical procedure, enabling clinical researchers to address the global organ shortage.
EGenesis Press Mentions
Stay in the know about the latest news on EGenesis
FDA OKs trial of pig livers as dialysis-like treatment for liver failure
statnews • Apr 16, 2025
Pig organ transplant company to enter clinical trials
bizjournals • Apr 15, 2025
Egenesis And Organox Announce U.S. FDA Clearance Of Ind Application For The Treatment Of Patients With Acute-On-Chronic Liver Failure
marketscreener • Apr 15, 2025
FDA OKs trial of pig livers as dialysis-like treatment for liver failure
apnews • Apr 15, 2025
Comprehensive Insights Of The Global Acute On Chronic Liver Failure (ACLF) Market: Key Drivers, Trends, Growth
einpresswire • Mar 26, 2025
EGenesis Management
Leadership team at EGenesis
Chief Operating Officer
Kenneth Fan
Executive Vice President of Research and Development
William Westlin
Join now and verify your accreditation status to gain access to:
- EGenesis Current Valuation
- EGenesis Stock Price
- EGenesis Management
- Available deals in EGenesis and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- EGenesis Cap Table and Funding History by Share Class and Liquidity Preferences
- EGenesis Revenue and Financials
- EGenesis Highlights
- EGenesis Business Model
- EGenesis Risk Factors
- EGenesis Research Report from SACRA Research
Trading EGenesis Stock
How to invest in EGenesis stock?
Accredited investors can buy pre-IPO stock in companies like EGenesis through EquityZen funds. These investments are made available by existing EGenesis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell EGenesis stock?
Shareholders can sell their EGenesis stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
